Chase has worked at the forefront of CRISPR biology and technologies for almost a decade, and he endeavors to translate biological insights into the next generation of tools for genome editing.

In 2018, Chase Beisel joined the Helmholtz Institute for RNA-based Infection Research in Würzburg, Germany, to lead the RNA Synthetic Biology group, and he holds a joint professorship as part of the medical faculty of the Julius-Maximilians University of Würzburg. His research group focuses on understanding the full diversity of CRISPR-Cas immune systems in bacteria and archaea and how these systems can be harnessed to advance the study, diagnosis, and treatment of infectious disease. Through these efforts, he is helping develop CRISPR as an ever-advancing tool for genome editing and brings extensive experience with the ensuing technologies. Prior to joining the HIRI, he was an associate professor in the chemical and biomolecular engineering department at North Carolina State University. While at NCSU, he co-founded Locus Biosciences to commercialize CRISPR as a programmable antimicrobial agent. Chase was a postdoctoral fellow at the National Institutes of Health and obtained his Ph.D. from the California Institute of Technology and his B.S. from Iowa State University, with both degrees in chemical engineering.